On May 17, 2023, the breakthrough results of a study evaluating the NETROD® Mesh Multi-Electrode Renal Artery Radiofrequency Ablation System were unveiled at the prestigious European Interventional Cardiology Conference (EUROPCR 2023), a leading global event in the cardiovascular field. This significant announcement further strengthens the body of evidence supporting the effectiveness and safety of the clinical RDN treatment, marking another milestone in the journey towards advancing patient care.
according to the Health China action (2019-2030) , "The prevalence rate among adults aged 18 and over in China is 27.5% , and there are 1.28 billion patients worldwide", "HYPERTENSION" -World Health Organization, NOUBIAP ET Al. Heart 2018 and other literature shows: “Our current blood pressure control rate is 17.8% , the worldwide blood pressure control rate is only 21% .”
RF RDN Enterprises Designated as FDA "Breakthrough Device
Approved for the NMPA Special Review Channel for Innovative Medical Devices
A Defender, Innovator, and Leader in the RDN Field
Achieved a breakthrough from 1st-generation to 3rd-generation RDN ablation catheter design, expanding the RDN ablation range from points and lines to comprehensive continuous energy field ablation.
Brattea goal with RDN is to provide lifelong benefits to hypertension patients through a single minimally invasive procedure.
Copyright © 2025 Brattea All Rights Reserved
Address: 138 Xinjun Ring Rd, Bulding 4 Unit 202, Minhang District, Shanghai 201114
Phone: +86-21-5496 1855
Email:global@brattea.com
